Document is current
Any future updates will be listed below
-
Authors
Mentz, Michael
Keay, William https://orcid.org/0000-0002-8794-7322
Strobl, Carolin Dorothea https://orcid.org/0000-0003-2257-6281
Antoniolli, Martina https://orcid.org/0000-0003-2720-9886
Adolph, Louisa
Heide, Michael
Lechner, Axel
Haebe, Sarah
Osterode, Elisa https://orcid.org/0000-0003-4359-2096
Kridel, Robert https://orcid.org/0000-0003-0287-7124
Ziegenhain, Christoph https://orcid.org/0000-0003-2208-4877
Wange, Lucas Esteban https://orcid.org/0000-0002-3275-9156
Hildebrand, Johannes Adrian https://orcid.org/0000-0002-5451-8038
Shree, Tanaya https://orcid.org/0000-0003-0694-3512
Silkenstedt, Elisabeth
Staiger, Annette M. https://orcid.org/0000-0002-5896-3200
Ott, German
Horn, Heike
Szczepanowski, Monika
Richter, Julia https://orcid.org/0000-0002-9543-4084
Levy, Ronald
Rosenwald, Andreas
Enard, Wolfgang
Zimber-Strobl, Ursula https://orcid.org/0000-0002-9765-5251
von Bergwelt-Baildon, Michael
Hiddemann, Wolfgang
Klapper, Wolfram https://orcid.org/0000-0001-7208-4117
Schmidt-Supprian, Marc
Rudelius, Martina
Bararia, Deepak
Passerini, Verena
Weigert, Oliver https://orcid.org/0000-0002-0987-7373
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SCHM2440/8-1, WE 4679/2-1)
Deutsche Krebshilfe (110659, 70112997)
Else Kröner-Fresenius-Stiftung (2021_EKES.13)
- License Information
-
More Information
Article History
Received: 13 February 2022
Revised: 21 June 2022
Accepted: 29 June 2022
First Online: 18 July 2022
Competing interests
: This research was supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Project-ID WE 4679/2-1 (OW), SCHM2440/8-1 (MSS), and the Max-Eder Program of the Deutsche Krebshilfe e.V. (DKH, German Cancer Aid), Project-ID 110659/70112997 (OW). OW is supported by an Else-Kröner Excellence Fellowship from the Else-Kröner-Fresenius Stiftung (Project-ID 2021_EKES.13). LA is supported by the Else Kröner-Fresenius Clinician Scientist Program: Cancer immunotherapy, and the Munich Clinician Scientist Program (MCSP). LA and JAH are supported by the German Consortium for Translational Cancer Research (DKTK) School of Oncology. MS, Amgen, Speakers Bureau. The authors declare no competing interests.
